All type of patients: 1 trials - HINT (nifedipine vs metoprolol)
| nifedipine vs metoprolol | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Acute (short term) treatment: 11 trials - Muller - Gordon - Eisenberg - Bradagan - Jaffe - Gottlieb - Erbel - Loogna - TRENT (Wilcox) - Walker - Sirnes
| nifedipine vs | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| reinfarction | no data | | confirmed myocardial infarction | 0.99 [0.46 2.12] | p=1.00 | 0 | 207 | 2 | Muller,Gordon, | | cardiac death | no data | | All cause death | 2.81 [0.64 12.40] | p=1.00 | 0 | 207 | 2 | Muller,Gordon, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nifedipine vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| reinfarction | no data | | confirmed myocardial infarction | 1.00 [0.89 1.12] | p=1.00 | 0 | 5683 | 9 | Eisenberg,Bradagan,Jaffe,Gottlieb,Erbel,Loogna,TRENT (Wilcox),Walker,Sirnes, | | cardiac death | no data | | All cause death | 1.11 [0.89 1.37] | p=1.00 | 0 | 5425 | 8 | Eisenberg,Bradagan,Jaffe,Gottlieb,Erbel,TRENT (Wilcox),Walker,Sirnes, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Acute short term and post MI studies: 14 trials - Muller - Gordon - Eisenberg - Bradagan - Jaffe - Gottlieb - Erbel - SPRINT I - SPRINT II - MI study group - Loogna - TRENT (Wilcox) - Walker - Sirnes
| nifedipine vs | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| reinfarction | no data | | confirmed myocardial infarction | 0.99 [0.46 2.12] | p=1.00 | 0 | 207 | 2 | Muller,Gordon, | | cardiac death | no data | | All cause death | 1.07 [0.85 1.35] | p=1.00 | 0 | 1999 | 3 | Muller,Gordon,MI study group, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nifedipine vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| reinfarction | 0.92 [0.62 1.36] | p=1.00 | 0 | 2276 | 1 | SPRINT I, | | confirmed myocardial infarction | 1.00 [0.90 1.11] | p=1.00 | 0 | 7041 | 10 | Eisenberg,Bradagan,Jaffe,Gottlieb,Erbel,SPRINT II,Loogna,TRENT (Wilcox),Walker,Sirnes, | | cardiac death | 1.01 [0.69 1.50] | p=1.00 | 0 | 2276 | 1 | SPRINT I, | | All cause death | 1.10 [0.94 1.29] | p=1.00 | 0 | 9059 | 10 | Eisenberg,Bradagan,Jaffe,Gottlieb,Erbel,SPRINT I,SPRINT II,TRENT (Wilcox),Walker,Sirnes, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Long term studies: 3 trials - SPRINT I - SPRINT II - MI study group
| nifedipine vs | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| reinfarction | no data | | confirmed myocardial infarction | no data | | cardiac death | no data | | All cause death | 1.05 [0.83 1.32] | p=1.00 | 0 | 1792 | 1 | MI study group, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nifedipine vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| reinfarction | 0.92 [0.62 1.36] | p=1.00 | 0 | 2276 | 1 | SPRINT I, | | confirmed myocardial infarction | 0.96 [0.71 1.31] | p=1.00 | 0 | 1358 | 1 | SPRINT II, | | cardiac death | 1.01 [0.69 1.50] | p=1.00 | 0 | 2276 | 1 | SPRINT I, | | All cause death | 1.10 [0.87 1.38] | p=1.00 | 0 | 3634 | 2 | SPRINT I,SPRINT II, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with hypertension: 1 trials - INSIGHT (diabetic subgroup)
| nifedipine vs coamilozide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.99 [0.69 1.42] | p=1.00 | 0 | 1302 | 1 | INSIGHT (diabetic subgroup), | | Cardiovascular death | 1.01 [0.53 1.92] | p=1.00 | 0 | 1302 | 1 | INSIGHT (diabetic subgroup), | | myocardial infarction (fatal and non fatal) | 1.13 [0.65 1.95] | p=1.00 | 0 | 1302 | 1 | INSIGHT (diabetic subgroup), | | stroke (fatal and non fatal) | 0.90 [0.46 1.75] | p=1.00 | 0 | 1302 | 1 | INSIGHT (diabetic subgroup), | | microvascular events | no data | | Non fatal MI | no data | | All cause death | 0.75 [0.52 1.09] | p=1.00 | 0 | 1302 | 1 | INSIGHT (diabetic subgroup), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with or without hypertension: 1 trials - INSIGHT (diabetic subgroup)
| nifedipine vs coamilozide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.99 [0.69 1.42] | p=1.00 | 0 | 1302 | 1 | INSIGHT (diabetic subgroup), | | Cardiovascular death | 1.01 [0.53 1.92] | p=1.00 | 0 | 1302 | 1 | INSIGHT (diabetic subgroup), | | myocardial infarction (fatal and non fatal) | 1.13 [0.65 1.95] | p=1.00 | 0 | 1302 | 1 | INSIGHT (diabetic subgroup), | | stroke (fatal and non fatal) | 0.90 [0.46 1.75] | p=1.00 | 0 | 1302 | 1 | INSIGHT (diabetic subgroup), | | microvascular events | no data | | Non fatal MI | no data | | All cause death | 0.75 [0.52 1.09] | p=1.00 | 0 | 1302 | 1 | INSIGHT (diabetic subgroup), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patient: 2 trials - INSIGHT - Castel
| nifedipine vs atenolol+chlorthalidone | No demonstrated result suggested Heart failure by 216% (not demonstrated) suggested All cause death by 72% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.73 [0.98 3.05] | p=1.00 | 0 | 351 | 1 | Castel, | | Cardiovascular death | no data | | stroke (fatal and non fatal) | 1.40 [0.40 4.94] | p=1.00 | 0 | 351 | 1 | Castel, | | Coronary event | 1.09 [0.40 3.00] | p=1.00 | 0 | 351 | 1 | Castel, | | Fatal MI | no data | | Non fatal MI | no data | | Heart failure | 3.16 [1.33 7.48] | p=0.04 | 0 | 351 | 1 | Castel, | | Diabetes onset | no data | | Angina | no data | | Peripheral arterial disease | no data | | End stage renal disease | no data | | Revascularization | no data | | All cause death | 1.72 [1.06 2.80] | p=0.04 | 0 | 351 | 1 | Castel, | | Fatal stroke | no data | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nifedipine vs hydrochlorothiazide+amiloride | No demonstrated result suggested Fatal MI by 221% (not demonstrated) suggested Diabetes onset by 30% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.07 [0.88 1.30] | p=1.00 | 0 | 6321 | 1 | INSIGHT, | | Cardiovascular death | 1.17 [0.84 1.65] | p=1.00 | 0 | 6321 | 1 | INSIGHT, | | stroke (fatal and non fatal) | 0.94 [0.69 1.29] | p=1.00 | 0 | 6321 | 1 | INSIGHT, | | Coronary event | 1.10 [0.83 1.47] | p=1.00 | 0 | 6321 | 1 | INSIGHT, | | Fatal MI | 3.21 [1.17 8.77] | p=0.04 | 0 | 6321 | 1 | INSIGHT, | | Non fatal MI | 1.09 [0.76 1.57] | p=1.00 | 0 | 6321 | 1 | INSIGHT, | | Heart failure | 1.75 [0.95 3.25] | p=1.00 | 0 | 6321 | 1 | INSIGHT, | | Diabetes onset | 0.70 [0.54 0.92] | p=0.04 | 0 | 6321 | 1 | INSIGHT, | | Angina | no data | | Peripheral arterial disease | no data | | End stage renal disease | no data | | Revascularization | no data | | All cause death | 1.03 [0.83 1.27] | p=1.00 | 0 | 6321 | 1 | INSIGHT, | | Fatal stroke | 1.09 [0.48 2.48] | p=1.00 | 0 | 6321 | 1 | INSIGHT, | | Non fatal stroke | 0.87 [0.61 1.26] | p=1.00 | 0 | 6321 | 1 | INSIGHT, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Diabetic patients : 1 trials - INSIGHT (diabetic subgroup)
| nifedipine vs coamilozide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.99 [0.69 1.42] | p=1.00 | 0 | 1302 | 1 | INSIGHT (diabetic subgroup), | | Cardiovascular death | 1.01 [0.53 1.92] | p=1.00 | 0 | 1302 | 1 | INSIGHT (diabetic subgroup), | | myocardial infarction (fatal and non fatal) | 1.13 [0.65 1.95] | p=1.00 | 0 | 1302 | 1 | INSIGHT (diabetic subgroup), | | stroke (fatal and non fatal) | 0.90 [0.46 1.75] | p=1.00 | 0 | 1302 | 1 | INSIGHT (diabetic subgroup), | | microvascular events | no data | | Non fatal MI | no data | | All cause death | 0.75 [0.52 1.09] | p=1.00 | 0 | 1302 | 1 | INSIGHT (diabetic subgroup), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Elderly (60 years and more): 1 trials - Castel
| nifedipine vs atenolol+chlorthalidone | No demonstrated result suggested Heart failure by 216% (not demonstrated) suggested All cause death by 72% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.73 [0.98 3.05] | p=1.00 | 0 | 351 | 1 | Castel, | | Cardiovascular death | no data | | stroke (fatal and non fatal) | 1.40 [0.40 4.94] | p=1.00 | 0 | 351 | 1 | Castel, | | Coronary event | 1.09 [0.40 3.00] | p=1.00 | 0 | 351 | 1 | Castel, | | Fatal MI | no data | | Non fatal MI | no data | | Heart failure | 3.16 [1.33 7.48] | p=0.04 | 0 | 351 | 1 | Castel, | | Diabetes onset | no data | | Angina | no data | | Peripheral arterial disease | no data | | End stage renal disease | no data | | Revascularization | no data | | All cause death | 1.72 [1.06 2.80] | p=0.04 | 0 | 351 | 1 | Castel, | | Fatal stroke | no data | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with additional risk factor: 1 trials - INSIGHT
| nifedipine vs hydrochlorothiazide+amiloride | No demonstrated result suggested Fatal MI by 221% (not demonstrated) suggested Diabetes onset by 30% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.07 [0.88 1.30] | p=1.00 | 0 | 6321 | 1 | INSIGHT, | | Cardiovascular death | 1.17 [0.84 1.65] | p=1.00 | 0 | 6321 | 1 | INSIGHT, | | stroke (fatal and non fatal) | 0.94 [0.69 1.29] | p=1.00 | 0 | 6321 | 1 | INSIGHT, | | Coronary event | 1.10 [0.83 1.47] | p=1.00 | 0 | 6321 | 1 | INSIGHT, | | Fatal MI | 3.21 [1.17 8.77] | p=0.04 | 0 | 6321 | 1 | INSIGHT, | | Non fatal MI | 1.09 [0.76 1.57] | p=1.00 | 0 | 6321 | 1 | INSIGHT, | | Heart failure | 1.75 [0.95 3.25] | p=1.00 | 0 | 6321 | 1 | INSIGHT, | | Diabetes onset | 0.70 [0.54 0.92] | p=0.04 | 0 | 6321 | 1 | INSIGHT, | | Angina | no data | | Peripheral arterial disease | no data | | End stage renal disease | no data | | Revascularization | no data | | All cause death | 1.03 [0.83 1.27] | p=1.00 | 0 | 6321 | 1 | INSIGHT, | | Fatal stroke | 1.09 [0.48 2.48] | p=1.00 | 0 | 6321 | 1 | INSIGHT, | | Non fatal stroke | 0.87 [0.61 1.26] | p=1.00 | 0 | 6321 | 1 | INSIGHT, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - Whitworth
| nifedipine vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 3 trials - SPRINT I - SPRINT II - MI study group
| nifedipine vs | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| reinfarction | no data | | confirmed myocardial infarction | no data | | cardiac death | no data | | All cause death | 1.05 [0.83 1.32] | p=1.00 | 0 | 1792 | 1 | MI study group, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nifedipine vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| reinfarction | 0.92 [0.62 1.36] | p=1.00 | 0 | 2276 | 1 | SPRINT I, | | confirmed myocardial infarction | 0.96 [0.71 1.31] | p=1.00 | 0 | 1358 | 1 | SPRINT II, | | cardiac death | 1.01 [0.69 1.50] | p=1.00 | 0 | 2276 | 1 | SPRINT I, | | All cause death | 1.10 [0.87 1.38] | p=1.00 | 0 | 3634 | 2 | SPRINT I,SPRINT II, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
